Table 2.
Results of axitinib management.
| Initial dose (mg/day) | |
| Median (range) | 10 (6–10) |
| Duration (month) | |
| Median month (range) | 9 (1–67) |
| Current treatment status, n (%) | |
| Continue | 12 (19.0) |
| Discontinuation | 51 (81.0) |
| Cause of discontinuation | |
| PD | 37 (58.7) |
| AE | 12 (19.0) |
| Others | 2 (3.2) |
| Objective response rate, n (%) | |
| CR + PR | 25 (39.7) |
| Best response, n (%) | |
| CR | 2 (3.2) |
| PR | 23 (36.5) |
| SD | 23 (36.5) |
| PD | 12 (19.0) |
| Not assessed | 3 (4.8) |
PD progressive disease, AE adverse event, CR complete response, PR partial response, SD stabel disease.